Clinical trials
Withdrawn Cataract trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
44 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 6 |
| 2022 | 3 |
| 2023 | 3 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 44 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alcon Research | 9 |
| Beaver-Visitec International, Inc. | 2 |
| EyePoint Pharmaceuticals, Inc. | 2 |
| Medical University of South Carolina | 2 |
| Advanced Ophthalmic Pharma | 1 |
| Asociación para Evitar la Ceguera en México | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Bucci Laser Vision Institute | 1 |
| Carl Zeiss Meditec AG | 1 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cataract | 44 |
| Astigmatism | 3 |
| Presbyopia | 3 |
| Aphakia | 2 |
| Vision Disorders | 2 |
| Amblyopia | 1 |
| Blindness | 1 |
| Corneal Endothelial Cell Loss | 1 |
| Diabetes Mellitus | 1 |
| Diabetic Retinopathy | 1 |
Trials
Showing 51 to 44 of 44. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.